



May 8, 2025

Matthew Hill, Health Physicist (Licensing)  
NRC Materials Licensing Branch, RIII  
2056 Westings Avenue, Suite 400  
Naperville, IL 60563-2657

Dear Mr. Hill:

As requested, listed are Dr. Erich Smith's supervised work experience/training hours. This work experience/training is to cover CFR 35.390(C)(1). Our Radiology director went over with him what you discussed on your phone conversation as well as shared the letter sent from you on April 23, 2025. Documentation for authorized user, Benjamin L. Vigilanti MD, will be attached.

Bell Hospital is requesting Erich Smith, MD be named as authorized user on NRC Materials License and be authorized under 35.100, 35.200 and 35.300. Please continue to review our application for the following: License No. 21-02037-01, Docket No. 030-13856, Control No. 646008

Nuclear medicine supervised work experience for Dr. Erich Smith with nuclear medicine training, clinic days, class and lab, and associated hours. Applicable training to CFR 35.390 b)(1)(i) through (b)(1)(ii)(E).

40 hours – July 8 to August 9, 2020; April 12-15, 2021; April 19-23, 2021, April 26-30, 2021; March 13-17, 2023; March 27-31, 2023; April 3-7, 2023; September 25-29, 2023; October 2-6, 2023; February 5-9, 2024; February 19-23, 2024; March 4-8, 2024; April 8-12, 2024

**Corrective Action:** Our previous letter missed a timeframe indicating the nuclear medicine supervised work experience with nuclear medicine training, clinic days, class and lab and associated hours for Dr. Erich Smith the week of April 15-April 19, 2024. This was an additional 40 hour of training.

32 hours – May 3-6, 2021; December 20-23, 2021; January 10-13, 2022; September 19-22, 2023;

24 hours – January 4-7, 2022

4 hours – October 10 and October 12, 2023

80 hours – February 20, to April 18, 2024

**TOTAL 800 hours** of supervised work experience and training which is applicable to CFR 35.390 b)(1)(i) through (b)(1)(ii)(E).

Of these, 560 hours are class and lab training which is applicable to CFR 35.390 b)(1)(i) through (b)(1)(ii)(E) and also includes patient evaluation, appropriateness and safety of treatment, radiation safety, and handling of radiotherapeutics before, during, and after treatments.

Please let me know if additional information is needed.

Sincerely,  
  
Mitch Leckelt, CEO

901 Lakeshore Dr. | Ishpeming, MI 49849  
906.486.4431 | UPHealthSystem.com